Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1135289.RAckauKllk9uawRopxWXQs0kCUXMwFqacKXQkMtMbsKws130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1135289.RAckauKllk9uawRopxWXQs0kCUXMwFqacKXQkMtMbsKws130_assertion type Assertion NP1135289.RAckauKllk9uawRopxWXQs0kCUXMwFqacKXQkMtMbsKws130_head.
- NP1135289.RAckauKllk9uawRopxWXQs0kCUXMwFqacKXQkMtMbsKws130_assertion description "[Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1135289.RAckauKllk9uawRopxWXQs0kCUXMwFqacKXQkMtMbsKws130_provenance.
- NP1135289.RAckauKllk9uawRopxWXQs0kCUXMwFqacKXQkMtMbsKws130_assertion evidence source_evidence_literature NP1135289.RAckauKllk9uawRopxWXQs0kCUXMwFqacKXQkMtMbsKws130_provenance.
- NP1135289.RAckauKllk9uawRopxWXQs0kCUXMwFqacKXQkMtMbsKws130_assertion SIO_000772 24323026 NP1135289.RAckauKllk9uawRopxWXQs0kCUXMwFqacKXQkMtMbsKws130_provenance.
- NP1135289.RAckauKllk9uawRopxWXQs0kCUXMwFqacKXQkMtMbsKws130_assertion wasDerivedFrom befree-2016 NP1135289.RAckauKllk9uawRopxWXQs0kCUXMwFqacKXQkMtMbsKws130_provenance.
- NP1135289.RAckauKllk9uawRopxWXQs0kCUXMwFqacKXQkMtMbsKws130_assertion wasGeneratedBy ECO_0000203 NP1135289.RAckauKllk9uawRopxWXQs0kCUXMwFqacKXQkMtMbsKws130_provenance.